{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:04:25Z","timestamp":1788260665619,"version":"build-2803163510"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T00:00:00Z","timestamp":1512000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III (ES)","award":["PI14\/00540"],"award-info":[{"award-number":["PI14\/00540"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0188303","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T18:18:02Z","timestamp":1512065882000},"page":"e0188303","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5935-3076","authenticated-orcid":true,"given":"Teresa","family":"Broquetas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Garcia-Retortillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Puigveh\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Cabrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Dolors","family":"Gim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Sol\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,11,30]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cld.2016.07.001","article-title":"Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities","volume":"20","author":"S Boucle","year":"2016","journal-title":"Clinics in liver disease"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1440-1746.2011.06695.x","article-title":"Natural history of chronic hepatitis B REVEALed","volume":"26","author":"CJ Chen","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","article-title":"Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response","volume":"5","author":"HL Chan","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2010.01.014","article-title":"Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective","volume":"52","author":"J Jaroszewicz","year":"2010","journal-title":"J Hepatol"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"MR Brunetto","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"MR Brunetto","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"MJ Sonneveld","year":"2010","journal-title":"Hepatology"},{"issue":"24","key":"ref8","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.3748\/wjg.v20.i24.7686","article-title":"Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues","volume":"20","author":"CH Chen","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jhep.2010.07.046","article-title":"Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir","volume":"54","author":"JG Reijnders","year":"2011","journal-title":"J Hepatol"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency","volume":"11","author":"DK Wong","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jhep.2010.10.027","article-title":"Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B","volume":"55","author":"EK Manesis","year":"2011","journal-title":"J Hepatol"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.26376","article-title":"Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy","volume":"58","author":"WK Seto","year":"2013","journal-title":"Hepatology"},{"key":"ref13","article-title":"The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment","author":"CH Chen","year":"2014","journal-title":"J Hepatol"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jhep.2014.08.031","article-title":"Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study","volume":"62","author":"F Zoulim","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jhep.2014.07.019","article-title":"Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate","volume":"61","author":"P Marcellin","year":"2014","journal-title":"J Hepatol"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jir282","article-title":"Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss","volume":"204","author":"R Zoutendijk","year":"2011","journal-title":"J Infect Dis"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s10620-017-4448-7","article-title":"Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma","volume":"62","author":"M Riveiro-Barciela","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"P Bedossa","year":"1996","journal-title":"Hepatology"},{"issue":"6","key":"ref19","first-page":"1225","article-title":"Practice Guidelines Committee AAftSoLD. Chronic hepatitis B","volume":"34","author":"AS Lok","year":"2001","journal-title":"Hepatology"},{"key":"ref20","article-title":"EASL International Consensus Conference on Hepatitis B","year":"2003","journal-title":"J Hepatol"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B","volume":"50","year":"2009","journal-title":"J Hepatol"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/liv.12091","article-title":"Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D","volume":"33","author":"L Boglione","year":"2013","journal-title":"Liver Int"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3851\/IMP1866","article-title":"Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside\/nucleotide analogues","volume":"16","author":"J Jaroszewicz","year":"2011","journal-title":"Antivir Ther"},{"issue":"11\u201312","key":"ref25","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2036.2011.04888.x","article-title":"Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection","volume":"34","author":"JW Jang","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"ref26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/apt.13779","article-title":"Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B","volume":"44","author":"P Marcellin","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: A systematic review","volume":"63","author":"G Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"ref28","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","author":"P Lampertico","year":"2017","journal-title":"J Hepatol"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/13543784.2017.1333105","article-title":"New antivirals for the treatment of chronic hepatitis B","volume":"26","author":"V Soriano","year":"2017","journal-title":"Expert Opin Investig Drugs"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0188303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:32:44Z","timestamp":1540341164000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0188303"}},"subtitle":[],"editor":[{"given":"Isabelle","family":"Chemin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,30]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0188303","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,30]]}}}